Incyte (NASDAQ:INCY) Stock Gets Price Target Increase from Barclays

Incyte (NASDAQ:INCY) had its price objective raised by stock analysts at Barclays from $139.00 to $143.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s price target would indicate a potential upside of 17.33% from the stock’s previous close.

INCY has been the topic of a number of other reports. Oppenheimer set a $152.00 price objective on shares of Incyte in a report on Tuesday. TD Cowen upped their target price on Incyte from $138.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Stifel Nicolaus increased their price target on Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Wells Fargo & Company boosted their price objective on Incyte from $116.00 to $128.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 1st. Finally, BMO Capital Markets restated a “market perform” rating on shares of Incyte in a research note on Tuesday. Twelve research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus target price of $132.81.

Incyte Stock Up 4.3%

INCY traded up $5.07 during trading on Friday, hitting $121.87. 552,929 shares of the company’s stock were exchanged, compared to its average volume of 1,727,064. Incyte has a fifty-two week low of $89.25 and a fifty-two week high of $132.60. The stock has a market cap of $24.70 billion, a P/E ratio of 15.48, a PEG ratio of 4.83 and a beta of 0.74. The business’s 50 day moving average is $120.62 and its two-hundred day moving average is $108.07.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The business’s revenue was up 14.0% on a year-over-year basis. During the same period last year, the company earned $2.26 earnings per share. On average, sell-side analysts forecast that Incyte will post 1.97 earnings per share for the current year.

Insider Transactions at Incyte

In other Incyte news, insider Pablo Cagnoni sold 2,642 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $112.71, for a total transaction of $297,779.82. Following the sale, the insider owned 183,200 shares of the company’s stock, valued at $20,648,472. The trade was a 1.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Incyte

Several hedge funds have recently made changes to their positions in INCY. Oregon Public Employees Retirement Fund lifted its holdings in Incyte by 1.5% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 20,970 shares of the biopharmaceutical company’s stock worth $2,545,000 after purchasing an additional 300 shares in the last quarter. Gallacher Capital Management LLC purchased a new position in Incyte during the 3rd quarter valued at about $218,000. IPG Investment Advisors LLC purchased a new position in Incyte during the 3rd quarter valued at about $1,779,000. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Incyte during the 3rd quarter valued at about $1,123,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Incyte during the third quarter valued at about $7,498,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Quarterly revenue and guidance beat expectations. Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion consensus estimate. Its adjusted loss of $3.60 per share was narrower than expected, and full-year 2026 net-sales guidance increased to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion. Incyte Q3 results and raised guidance
• Positive Sentiment: Key products continued to show healthy demand. Opzelura sales rose 36% to $255 million, prompting higher 2026 guidance of $1.10 billion-$1.12 billion. Hematology and oncology portfolio sales increased 38% to $235 million, while Jakafi and Jakafi XR sales rose 4% to $827 million. Incyte product sales and guidance
• Positive Sentiment: Analyst sentiment provided additional support. Several analysts raised their price targets, and Guggenheim maintained a Buy rating. One forecast cited by Benzinga implies more than 23% potential upside from current levels. Analyst forecasts for Incyte
• Neutral Sentiment: Pipeline activity remains constructive but early stage. Adagene dosed the first patient in a Phase 1 study combining its therapy with Incyte’s INCA33890 in colorectal cancer. The program could expand Incyte’s oncology pipeline, although clinical benefits remain unproven. Adagene and Incyte Phase 1 study
• Negative Sentiment: The headline loss may weigh on shares. Incyte posted a GAAP net loss of approximately $785 million, or $3.86 per share, largely because of a $1.23 billion in-process research and development charge tied to its Vega Therapeutics acquisition. Commentary also characterized the valuation gap as largely closed after recent gains, leading one analyst to upgrade the stock only to Hold. Incyte valuation and analyst outlook

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.